Skip to content

Study · Randomized controlled trial · n = 30 · 1992

3 results

A trial of desmopressin to reduce blood loss in patients undergoing spinal fusion for idiopathic scoliosis.

Guay J, Reinberg C, Poitras B, David M, Mathews S, Lortie L, Rivard GE

Anesthesia and analgesia1 Sept 1992Cited by 45 (Europe PMC)

PMID1510262 (opens in a new tab)DOI10.1213/00000539-199209000-00016 (opens in a new tab)PepBankPUB-01510262
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In young scoliosis patients undergoing spinal fusion, intraoperative blood loss was similar with desmopressin and placebo.

    In plain wordsIn young scoliosis patients undergoing spinal fusion, intraoperative blood loss was similar with desmopressin and placebo.

    Peptide
    Desmopressin
    Outcome
    No significant changeIntraoperative blood loss
    Study

    n = 30

    Comparator
    Placebo
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10 micrograms/m2 of body surface areaAs given in this study (human).

    Measurements

    Blood loss
    57.4%
    DDAVP, SD 26.5
    Blood loss
    67%
    placebo, SD 28.8

    Source sentences

    Summary
    The amount of blood loss expressed as a percent of the estimated blood volume was similar in both groups during the intraoperative period (67.0% +/- 28.8% [mean +/- SD] placebo group vs 57.4% +/- 26.5% DDAVP group)
    1 context sentence
    Summary · context
    To evaluate its efficacy in normal patients, 30 healthy young patients (ASA physical status I or II) undergoing spinal fusion for idiopathic scoliosis were randomly allocated to receive either 100 mL of physiologic saline solution (placebo group) or DDAVP (10 micrograms/m2 of body surface area) (DDA…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In young scoliosis patients undergoing spinal fusion, postoperative blood loss through 24 h was similar with desmopressin and placebo.

    In plain wordsIn young scoliosis patients, postoperative blood loss through 24 h was similar with desmopressin and placebo.

    Peptide
    Desmopressin
    Outcome
    No significant changePostoperative blood loss through 24 hours
    Study

    n = 30

    Comparator
    Placebo
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10 micrograms/m2 of body surface areaAs given in this study (human).

    Measurements

    Blood loss
    31.1%
    DDAVP, SD 10.6
    Blood loss
    32.5%
    placebo, SD 6.4

    Source sentences

    Summary
    the postoperative period up to 24 h (32.5% +/- 6.4% placebo group vs 31.1% +/- 10.6% DDAVP group)
    1 context sentence
    Summary · context
    To evaluate its efficacy in normal patients, 30 healthy young patients (ASA physical status I or II) undergoing spinal fusion for idiopathic scoliosis were randomly allocated to receive either 100 mL of physiologic saline solution (placebo group) or DDAVP (10 micrograms/m2 of body surface area) (DDA…
  3. 03HumanRandomized controlled trialEfficacy outcome

    In young scoliosis patients undergoing spinal fusion, combined blood loss was similar with desmopressin and placebo.

    In plain wordsIn young scoliosis patients undergoing spinal fusion, combined blood loss was similar with desmopressin and placebo.

    Peptide
    Desmopressin
    Outcome
    No significant changeCombined intraoperative and postoperative blood loss
    Study

    n = 30

    Comparator
    Placebo
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    10 micrograms/m2 of body surface areaAs given in this study (human).

    Measurements

    Blood loss
    88.2%
    DDAVP, SD 30.7
    Blood loss
    94.3%
    placebo, SD 29.4

    Source sentences

    Summary
    and both periods (94.3% +/- 29.4% placebo group vs 88.2% +/- 30.7% DDAVP group).
    1 context sentence
    Summary · context
    To evaluate its efficacy in normal patients, 30 healthy young patients (ASA physical status I or II) undergoing spinal fusion for idiopathic scoliosis were randomly allocated to receive either 100 mL of physiologic saline solution (placebo group) or DDAVP (10 micrograms/m2 of body surface area) (DDA…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.